<DOC>
	<DOCNO>NCT01072162</DOCNO>
	<brief_summary>This randomize , open-label , five-period , balance crossover study conduct approximately 40 healthy adult subject enrol one study center USA . Subjects receive five eltrombopag treatment : tablet fast , Powder Oral Suspension ( PfOS ) fast , PfOS high calcium meal , PfOS 2 hour prior high calcium meal , PfOS 2 hour high calcium meal , treatment single 25 mg dose . There 10 14 day washout period , last dose study drug follow-up visit . During treatment period , subject undergo serial PK sample 72 hour measurement plasma eltrombopag concentration . Safety assess vital sign , clinical safety laboratory assessment , adverse event reporting .</brief_summary>
	<brief_title>Relative Bioavailibilty Pediatric Powder Suspension ( PfOS ) Formulation Food Effect</brief_title>
	<detailed_description>This randomize , open-label , five-period , balance crossover study conduct approximately 40 healthy adult subject enrol one study center USA . Subjects receive five eltrombopag treatment : tablet fast , PfOS fast , PfOS high calcium meal , PfOS 2 hour prior high calcium meal , PfOS 2 hour high calcium meal , treatment single 25 mg dose . There 10 14 day washout period , last dose study drug follow-up visit . During treatment period , subject undergo serial PK sample 72 hour measurement plasma eltrombopag concentration . Safety assess vital sign , clinical safety laboratory assessment , adverse event reporting .</detailed_description>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>1 . Healthy subject clinically significant abnormality identify physician evaluation medical history , physical examination , clinical laboratory test electrocardiogram ( ECG ) . 2 . Male female subject age 18 64 year age inclusive , time signing informed consent . 3 . Subject able understand comply protocol requirement , instruction restriction . 4 . Capable give write informed consent include compliance requirement restriction list consent form . 5 . Body weight ≥ 50kg ( 110 lb ) men ≥ 45 kg ( 99 lb ) woman body mass index ( BMI ) 18.5 29.9 kg/m2 inclusive . 6 . A platelet count within normal range &gt; 400,000 plt/uL . 7 . Male subject , surgically sterile , must agree abstinence use double barrier method , , condom plus spermicidal agent ( foam/gel/film/cream/suppository ) . This criterion must follow time first dose study medication 14 day last dose medication . 8 . A female subject eligible participate neither pregnant lactating , fall one follow category : nonchildbearing potential include premenopausal female document ( medical report verification ) hysterectomy bilateral oophorectomy , postmenopausal female define amenorrheic great one year serum estradiol follicle stimulate hormone level consistent menopause . childbearing potential negative beta human chorionic gonadotropin ( beta/hCG ) test agree comply recognize nonhormonal contraceptive method screen least two week prior first dose ( whichever earlier ) followup visit . Recognized nonhormonal contraceptive method include : complete abstinence intercourse , male partner sterilization , two form barrier contraception ( e.g . condom occlusive cap ( diaphragm cervical/vault cap spermicide ) , intrauterine device ( IUD ) , intrauterine system ( IUS ) &lt; 1 % failure rate state product label . 1 . History Gilbert 's syndrome . 2 . Any previous history deep vein thrombosis thromboembolic event . 3 . History thrombocytopenia bleed due abnormal platelet number function . 4 . Clotting factor abnormality associate hypercoagulability , specifically Factor V Leiden , Protein C Protein S deficiency antithrombin III deficiency . 5 . Elevated blood pressure ( BP ) screening ( systolic &gt; 140 mm Hg , diastolic &gt; 85 mm Hg ) . If subject 's BP elevate first measurement , complete two additional BP measurement two minute apart average three assessment evaluate criterion . If average BP exceed safety criterion , subject exclude . 6 . History atrial fibrillation , mitral valve prolapse , significant heart murmur vascular bruit . 7 . Prolonged QTc interval ( Bazett 's ) screening ( female &gt; 450 msec male &gt; 430 msec ) . If QTc interval prolong initial ECG , complete two additional ECGs 5 minute apart take average QTc measurement three ECGs evaluate criterion . If average QTc exceed safety criterion , subject exclude . 8 . Female subject currently receive hormone replacement therapy ( HRT ) . 9 . Positive HIV , hepatitis B virus hepatitis C virus assay screen . 10 . Positive urine drug screen include alcohol screen predose ( Day 1 ) . 11 . History alcohol/drug abuse dependence within 12 month study . 12 . History alcohol consumption past six month exceed 7 units/week woman 14 units/week men ( 1 unit = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) . 13 . Urinary cotinine level indicative smoking screen predose ( Day 1 ) . History regular use tobacco nicotinecontaining product within 6 month prior screen . 14 . Treatment investigational drug within 30 day five halflives ( whichever longer ) precede first dose study medication . 15 . Exposure four new chemical entity within 12 month prior first dose day . 16 . Use prescription nonprescription drug ( include aspirin nonsteroidal antiinflammatory drug [ NSAIDs ] ) , vitamin , herbal dietary supplement within seven day ( 14 day drug potential enzyme inducer , St. John 's Wort ) five halflives ( whichever longer ) prior first dose study medication , unless opinion investigator sponsor medication interfere study procedure compromise subject safety . 17 . Subjects donate plasma within seven day prior screen visit participation study would result donation blood excess 500 mL within 56day period . 18 . History sensitivity study medication , component thereof .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>healthy</keyword>
	<keyword>powder suspension</keyword>
	<keyword>tablet</keyword>
	<keyword>bioavailibility</keyword>
	<keyword>eltrombopag</keyword>
</DOC>